O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
about
O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liverModulation of dynamin-related protein 1 (DRP1) function by increased O-linked-β-N-acetylglucosamine modification (O-GlcNAc) in cardiac myocytes.Stable Isotope Labeling with Amino Acids (SILAC)-Based Proteomics of Primary Human Kidney Cells Reveals a Novel Link between Male Sex Hormones and Impaired Energy Metabolism in Diabetic Kidney Disease.Decreased O-GlcNAcylation of the key proteins in kinase and redox signalling pathways is a novel mechanism of the beneficial effect of α-lipoic acid in diabetic liver.The Role of Stress-Induced O-GlcNAc Protein Modification in the Regulation of Membrane Transport.
P2860
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
@ast
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
@en
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
@nl
type
label
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
@ast
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
@en
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
@nl
prefLabel
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
@ast
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
@en
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.
@nl
P2860
P1476
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease
@en
P2093
Udayakumar Karunakaran
P2860
P304
P356
10.4093/KDJ.2010.34.4.211
P577
2010-08-31T00:00:00Z